Influence of renal function on blood pressure control and outcome in thrombolyzed patients after acute ischemic stroke: post-hoc analysis of the ENCHANTED trial

Front Endocrinol (Lausanne). 2024 Dec 9:15:1341902. doi: 10.3389/fendo.2024.1341902. eCollection 2024.

Abstract

Background: The effect of renal impairment in patients who receive intravenous thrombolysis for acute ischemic stroke (AIS) is unclear. We aimed to determine the associations of renal impairment and clinical outcomes and any modification of the effect of intensive versus guideline-recommended blood pressure (BP) control in the BP arm of the International Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED).

Methods: We conducted a post-hoc analysis of the ENCHANTED BP arm, which involved 2,196 thrombolyzed AIS patients. Logistic regression models were used to define the association between eGFR and clinical outcomes of death, death or major disability [modified Rankin scale (mRS) scores 3-6], and major disability (mRS 3-5) at 90 days.

Results: Of the 2,151 patients with available baseline renal function data (mean age 66.9 years; 38% women), 993 (46.2%), 822 (38.2%), and 336 (15.6%) had normal (eGFR ≥ 90 mL/min/1.73 m2), mildly (60-89), and moderate-to-severely impaired (<60) renal function, respectively. Compared with patients with normal eGFR, mortality was higher in those with moderate-to-severe renal impairment (adjusted odds ratio 1.77, 95% confidence interval 1.05-2.99; p = 0.031 for trend). However, the difference in death or major disability (mRS 3-6) was not significant between groups. There was no heterogeneity in the effect of intensive versus guideline-recommended BP-lowering treatment on death by grades of renal function (p for interaction = 0.545).

Discussion: The presence of moderate-to-severe renal impairment is associated with increased mortality in thrombolyzed patients with AIS. Renal function does not modify the effect of early intensive BP-lowering treatment on death in this patient group.

Keywords: acute ischemic stroke; blood pressure; clinical outcome; renal function; thrombolysis.

Publication types

  • Randomized Controlled Trial
  • Multicenter Study

MeSH terms

  • Aged
  • Antihypertensive Agents / therapeutic use
  • Blood Pressure* / drug effects
  • Blood Pressure* / physiology
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Glomerular Filtration Rate*
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy
  • Hypertension / physiopathology
  • Ischemic Stroke* / drug therapy
  • Ischemic Stroke* / mortality
  • Ischemic Stroke* / physiopathology
  • Kidney / physiopathology
  • Male
  • Middle Aged
  • Thrombolytic Therapy / methods
  • Treatment Outcome

Substances

  • Antihypertensive Agents
  • Fibrinolytic Agents

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The main funding for the ENCHANTED trial was from the National Health and Medical Research Council (NHMRC) of Australia. Additional funding was from the Stroke Association (United Kingdom), the National Council for Scientific and Technological Development (Brazil; CNPQ: 467322/2014-7, 402388/2013-5), and the Ministry for Health, Welfare and Family Affairs (Republic of Korea; HI14C1985).